ENSG Heads Into Q1 Print With Options at a 52-Week Extreme

ENSG reports Q1 2026 results today — and options traders are the loudest voice in the room ahead of the bell.

The clearest pre-earnings signal is in options positioning. The put/call ratio has jumped to 1.27, a full 2.5 standard deviations above its 20-day average of 0.88, and that reading is the highest of the past 52 weeks. Demand for downside protection has grown sharply over the last several sessions — the PCR was running below 0.80 as recently as April 21. That's a swift pivot into hedging territory in the final days before the print.

The short side of the market tells a calmer story. Short interest runs at just 2.25% of free float — low enough that short sellers are not a primary force on this stock. The position is roughly flat on the week, down about 4% from seven days ago. Borrowing costs remain negligible at 0.45% annualised, and borrow availability is ample, with no signs of tightness in the lending market. The ORTEX short score is a moderate 34, well below levels that would signal any building short conviction. This is not a stock where the bear trade is crowded.

The Street's setup is more nuanced. Analysts carry a mean price target of $220, implying roughly 18% upside from Tuesday's close of $186.40. The most recent analyst actions, from February — RBC Capital maintaining Outperform with a raised target at $222 and Truist lifting its Hold target to $215 — were both post-Q4 reactions to a blowout quarter. That Q4 print in early February sent the stock up 14% in a single day and 24% over the following five sessions. The bar for a repeat is now considerably higher. The PE has compressed about 2.1 points over the past 30 days to 24x, and EV/EBITDA has drifted lower to 17.4x — the market has re-rated the stock modestly cheaper, down roughly 7% from its one-month high. Bulls point to consistent execution on same-store facilities, a strong acquisition pipeline, and robust demand for post-acute care. Bears flag Medicare Advantage pressures on length of stay, nursing labour costs, and a valuation that leaves little room for a guidance miss.

Institutional ownership is broadly constructive. BlackRock holds 12.2% of shares and added modestly in Q1. T. Rowe Price is the most active large holder, adding nearly 270,000 shares in the most recently reported quarter. Baillie Gifford, which built a 7.8% position, remains a significant long-term anchor. On the insider side, the 90-day net activity is positive in aggregate due to large stock awards to the President/COO and CFO in February, though several directors have been trimming small positions at prices in the $196–$200 range over the past few weeks — a routine pattern that does not suggest any unusual urgency.

Close peers have had a mixed week. PNTG, the most correlated post-acute care name, added 4.6% over seven days. UHS and HCA each fell more than 7% — but those are largely hospital operators exposed to different reimbursement pressures. RSI14 has slid to 33, signalling the stock is technically oversold after its 7% one-month decline.

What to watch on the call: the key question is whether Q1 revenue growth and same-facility metrics can sustain the trajectory that drove the February re-rating — and whether management's commentary on Medicare Advantage trends gives bulls any room to rebuild.